July 02, 2026
1 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
FDA rejects Galderma’s relabotulinumtoxinA for second time
The FDA declined to approve a biologics license application for Galderma’s relabotulinumtoxinA, citing manufacturing and testing concerns, according to a company press release. In its complete response letter, the FDA stated that “observations during manufacturing site inspection and analytical method optimization” need to be addressed, according to the release. The agency did
453 words~2 min read
